Stewart D, Bodey G P
J Antibiot (Tokyo). 1975 Feb;28(2):149-55. doi: 10.7164/antibiotics.28.149.
Sisomicin, a new aminoglycoside antibiotic which is produced by Micromonospora myoensis, was studied against 565 clinical isolates of gram-negative bacilli and gram-positive cocci. With the exception of Serratia marcescens, over 90% of isolates of gram-negative bacilli were inhibited by 1.56 mug/ml or less of sisomicin. Sisomicin was slightly more active than gentamicin and tobramycin aganist isolates of Escherichia coli, Proteus mirabilis and Klebsiella spp. It was substantially more active than butirosin and kanamycin against all gram-negative bacilli. Isolates of gram-negative bacilli which were resistant to gentamicin and tobramycin were also resistant to sisomicin. Most of these isolates were sensitive to amikacin.
西索米星是一种由肌动单孢菌产生的新型氨基糖苷类抗生素，我们用它对565株革兰氏阴性杆菌和革兰氏阳性球菌临床分离株进行了研究。除粘质沙雷氏菌外，90%以上的革兰氏阴性杆菌分离株可被1.56微克/毫升或更低浓度的西索米星抑制。在针对大肠杆菌、奇异变形杆菌和克雷伯菌属分离株方面，西索米星的活性略高于庆大霉素和妥布霉素。在针对所有革兰氏阴性杆菌方面，它的活性显著高于丁胺卡那霉素和卡那霉素。对庆大霉素和妥布霉素耐药的革兰氏阴性杆菌分离株对西索米星也耐药。这些分离株中的大多数对阿米卡星敏感。
